SCHEMBL4170118

SCHEMBL4170118

CC(=O)Nc1c(Cl)cnn(C)c1=O

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 3/20 0.52
KAT2B Q92831 4/20 0.44
BRD9 Q9H8M2 2/20 0.44
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
AHR P35869 1/20 0.40
CYP1A2 P05177 1/20 0.40
KDM4E B2RXH2 1/20 0.38
COPS5 Q92905 1/20 0.38
BRD4 O60885 1/20 0.38
LMNA P02545 1/20 0.38
NPBWR1 P48145 1/20 0.37
MCHR1 Q99705 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8547853 0.79 BPTF (0.58) BPTFKAT2BBRD9ALDH1A1HPGD
SCHEMBL4165192 0.78 BPTF (0.40) BPTFKAT2BBRD9SMN1; SMN2ALDH1A1
SCHEMBL4172546 0.76 SMN1; SMN2 (0.57) HTTSMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL71356 0.72 PDE4D (0.47) MAPT
SCHEMBL9123299 0.72 BPTF (0.66) BPTFKAT2BBRD9HTTSMN1; SMN2
SCHEMBL31735435 0.71 BPTF (0.43) BPTFKAT2BBRD9SMN1; SMN2BRD4
SCHEMBL2642058 0.71 KAT2B (0.47) BPTFKAT2BBRD9HTTSMN1; SMN2
SCHEMBL979278 0.70 KAT2B (0.60) BPTFKAT2BBRD9HTTSMN1; SMN2
SCHEMBL9982965 0.70 BPTF (0.68) BPTFKAT2BBRD9HTTSMN1; SMN2
SCHEMBL9124850 0.70 BPTF (0.68) BPTFKAT2BBRD9SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012088-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-01-08 US disclosed
US-20090012088-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-01-08 US disclosed
US-20090012088-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-01-08 US disclosed
US-20070032496-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2007-02-08 US disclosed
US-20070032496-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2007-02-08 US disclosed
US-20070032496-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032496-A1 Compounds for the Treatment of Neurodegeneration and Stroke PARP1, PARP12, PARP11 BPTF 3277/4885KAT2B 1749/4885BRD9 1742/4885
US-20090012088-A1 Compounds for the Treatment of Neurodegeneration and Stroke PARP1, PARP12, PARP11 BPTF 3277/4885KAT2B 1749/4885BRD9 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.